
Asian equities have rallied strongly in 2026, driven by surging AI infrastructure investment, robust semiconductor demand and improving corporate earnings. Taiwan and South Korea have been among the biggest beneficiaries, supported by heavy spending from global technology giants. However, after such a strong rally, investors are questioning whether the AI investment cycle has further room to run or whether much of the optimism is already priced in.
Beyond AI, Asia's investment landscape is evolving, with China's push for technological self-sufficiency, biotechnology breakthroughs and emerging industry leaders creating new growth opportunities. Yet, uneven economic recovery, geopolitical uncertainties and widening performance divergence across markets and sectors remain key challenges. As Asia enters its next phase of growth, identifying the right companies may become just as important as choosing the right markets.
Against this backdrop, the iFAST-Amova Asia Premier Trust offers investors an actively managed approach to capturing long-term growth opportunities across Asia excluding Japan. Sub-managed by Amova Asset Management, the fund seeks to capture Asia's structural growth opportunities through high-conviction investments in regional leaders across semiconductors, digital infrastructure and consumer innovation.
In this Q&A, we speak with Amova's investment team about the sustainability of Asia's AI-driven rally, emerging opportunities beyond semiconductors and the outlook for China. We also explore the fund's performance, key risks and the value of active stock selection in an increasingly divergent regional market.
1. AI and semiconductor investment have been major drivers of Asian equity markets this year, while Technology accounts for around 40% of the fund. How sustainable is the current AI investment cycle?
We believe the AI investment cycle remains sustainable, although it is likely to evolve rather than continue in a straight line. Today's AI ecosystem is still in the infrastructure build-out phase. Global cloud providers, hyperscalers and enterprises continue to invest heavily in data centres, networking equipment, memory, storage and semiconductor capacity. Importantly, the AI story is broadening beyond training large models. The next phase increasingly revolves around inference, where AI systems are deployed into real-world applications. This shift creates demand across a wider set of technologies including memory, networking, optical components, power management, cooling solutions and software.
That said, investors should expect periodic volatility. The key debate is no longer whether AI demand exists, but whether investment returns can justify the enormous capital expenditure currently underway. Eventually, bottlenecks may shift from chips toward power availability, grid infrastructure and data-centre deployment. We see these as signs of the cycle maturing rather than ending. We remain constructive on AI, but increasingly focus on where value accrues beyond the obvious semiconductor winners.
2. Beyond the major semiconductor holdings, where do you see the next layer of opportunities in Asia?
We would highlight the biotech sector in China. Many have heard about DeepSeek in China, but what is less known is that the biotech sector in China has also gone through its own DeepSeek moment.
We have known for some time now that China’s biotech industry has improved by leaps and bounds over the years given its large talent pool, population size, and a generally supportive regulatory environment. Importantly, Chinese biotech firms are at the forefront of innovative drug research such as cancer treatment research. The problem was that in the past, many people were sceptical about Chinese biotech data, and that changed significantly last year when a previously little-known Chinese biotech company, Akeso*, together with its US partner published topline data from their global phase 3 study, which was consistent with their China phase 3 data. Suddenly, there was a global recognition that China has a deep pipeline of very innovative and high-quality drugs. Since then, growth of drug out-licencing deals has been parabolic.
We think this growth will be exponential and can continue for a long time. This global recognition coincides with major global pharma companies facing patent cliffs of key blockbuster drugs in the coming 3-5 years. Global pharma companies are now urgently seeking to replenish their drug portfolios, and China has now emerged as a very important source of very innovative and high-quality drug pipeline.
*Reference to any particular securities or sectors is purely for illustrative purposes only and does not constitute a recommendation to buy, sell or hold any securities or to be relied upon as financial advice in any way.
3. China remains the largest market in the portfolio, but has underperformed broader Asia year-to-date. What is your current outlook for China, and what developments would make you more constructive—or more cautious—on the market?
China's economy continues to experience a K-shaped recovery, with export-oriented and technology-related sectors generally outperforming domestically focused industries. While property sector weakness and subdued consumer confidence remain as challenges, supportive liquidity conditions and gradually improving earnings trends are providing a firmer backdrop for equities. Policymakers continue to encourage greater participation in equity markets while selectively supporting strategic industries and innovation-oriented sectors.
Rather than relying on broad-based stimulus, we believe opportunities are increasingly concentrated in companies benefiting from technological self-sufficiency, advanced manufacturing, industrial upgrading and improving shareholder returns.
Key risks for China would include re-escalation of trade or technology tensions and renewed property weakness. Our base case remains that China is transitioning toward a more technology-driven, innovation-led growth model, but the path will not be linear.
4. What are the key risks that could challenge your investment thesis for Asian equities?
We would highlight three risks.
- In the event of an AI investment slowdown, a sharp reduction in hyperscaler spending would likely impact semiconductor demand and earnings expectations.
- The region also remains exposed to geopolitical risks as a deterioration in US-China relations or prolonged Middle East-related energy shocks could weigh on returns.
- Asian equities have enjoyed improving earnings expectations. If earnings growth fails to materialise, markets could re-rate lower.
5. How has the fund performed relative to its benchmark year-to-date and over the longer term? What have been the key drivers of outperformance or underperformance, particularly in terms of country allocation, sector positioning and stock selection?
The fund has modestly outperformed the MSCI All Country Asia ex Japan Index over the short term but lags over three years. Year-to-date, it returned 26.76% versus 26.64% for the benchmark (+0.11 percentage points, pp), and over one year 32.22% versus 31.16% (+1.06 pp). Over three years, it returned 23.27% per annum against 25.67%, an annualised shortfall of 2.40 pp.
On a country basis, allocation has detracted while stock selection within markets has been additive. Strong results in Taiwan and Korea, driven predominantly by stock selection, contributed 3.52 pp and 2.29 pp year-to-date and 7.96 pp and 5.33 pp over three years. India added a further 0.98 pp year-to-date and 4.79 pp over three years. On the flip side, China has been the biggest detractor.
From a sector perspective, the overweight in Information Technology has been the dominant positive, contributing 7.48 pp year-to-date, 8.65 pp over one year, and 6.92 pp over three years, supported by both allocation and selection. Industrials (−3.88 pp year-to-date) and Health Care (−1.32 pp) detracted, chiefly through stock selection, while Materials (−2.32 pp) was held back by both an overweight and weak holdings. Over three years, Financials was the largest sector detractor (−5.67 pp).
At the stock level, holdings in the North Asian semiconductor and technology hardware supply chain drove returns. Unimicron Technology (+3.70 pp), Elite Material (+2.74 pp), Samsung Electronics (+2.62 pp) and ASE Technology (+2.04 pp) were the top contributors year-to-date and also led over one and three years. The largest detractor was the underweight in MediaTek (−1.72 pp year-to-date; −2.09 pp over one year), alongside Chinese holdings including Dongfang Electric (−1.33 pp), GDS Holdings (−1.04 pp) and Goldwind Science & Technology (−1.03 pp). Over three years, MediaTek was again the largest detractor (−0.67 pp per annum), followed by Alibaba, Xiaomi and Dongfang Electric (−0.42 pp each). Overall, recent outperformance reflects successful stock selection in North Asian technology, partly offset by China positioning.
Source: FactSet. Data as of 30 September 2026.
6. Given the availability of low-cost, broad-based Asia ex-Japan index ETFs, what do you believe is the key value proposition of this fund for investors today?
Passive funds provide efficient market exposure. The question is whether the future opportunity set in Asia is likely to be evenly distributed. We believe it is not.
Asia today is characterised by significant divergence: winners versus losers in AI, consumption leaders versus laggards, reform beneficiaries versus reform disappointments, state-supported innovators versus legacy industries. An index must own everything while an active manager can be selective.
For example, while Asia's technology sector broadly benefits from AI, much of the economic value accrues to a relatively small number of companies operating within critical ecosystems such as semiconductors, memory, advanced packaging, power infrastructure and data centres.
Similarly, China's economy may be experiencing uneven growth, but selected businesses in AI infrastructure, advanced manufacturing and export-oriented industries continue to produce strong earnings growth.
At a time when structural winners are becoming increasingly concentrated, we believe active stock selection remains particularly valuable.
Declaration:
For specific disclosure, at the time of publication of this report, IFPL (via its connected and associated entities) and the analyst who produced this report hold a NIL position in the abovementioned securities.
Important
Information:
This document is purely for informational purposes only with no
consideration given to the specific investment objective, financial situation
and particular needs of any specific person. It should not be relied upon as
financial advice. Any securities mentioned herein are for illustration purposes
only and should not be construed as a recommendation for investment. You should
seek advice from a financial adviser before making any investment. In the event
that you choose not to do so, you should consider whether the investment
selected is suitable for you. Investments
in funds are not deposits in, obligations of, or guaranteed or insured by Amova
Asset Management Asia Limited (“Amova Asia”). Past performance or any
prediction, projection or forecast is not indicative of future performance.
The information contained herein may not be copied, reproduced or
redistributed without the express consent of Amova Asia. While reasonable care
has been taken to ensure the accuracy of the information, Amova Asia does not
give any warranty or representation, either express or implied, and expressly
disclaims liability for any errors or omissions. Information may be subject to
change without notice. Amova Asia accepts no liability for any loss, indirect
or consequential damages, arising from any use of or reliance on this document.
Amova Asset Management Asia Limited. Registration Number 198202562H.

